SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Front Cardiovasc Med. 2024;11:1346414.

Combination of early rhythm control and healthy lifestyle on the risk of stroke in elderly patients with new-onset atrial fibrillation: a nationwide population-based cohort study.

, , , , , ,

제1저자 임우현, 이소령 · 교신저자 최의근

소속 (7)
  1. Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
  2. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  3. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  4. Department of Medical Statistics, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea.
  5. Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea.
  6. Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Chest and Heart Hospital, Liverpool, United Kingdom.
  7. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Abstract

BACKGROUND The impact of early rhythm control (ERC) combined with healthy lifestyle (HLS) on the risk of ischemic stroke in elderly patients with atrial fibrillation (AF) remains unaddressed.

OBJECTIVE To evaluate the impact of combined ERC and HLS on the risk of stroke in elderly patients with new-onset AF.

METHODS Using the Korean National Health Insurance Service database, we included patients aged ≥75 years with new-onset AF from January 2009 to December 2016 (n = 41,315). Patients who received rhythm control therapy within 2 years of AF diagnosis were defined as the ERC group. Non-smoking, non-to-mild alcohol consumption (<105 g/week), and regular exercise were defined as HLS. Subjects were categorized into four groups: group 1 (without ERC and HLS, n = 25,093), 2 (HLS alone, n = 8,351), 3 (ERC alone, n = 5,565), and 4 (both ERC and HLS, n = 2,306). We assessed the incidence of ischemic stroke as the primary outcome, along with admissions for heart failure, all-cause death, and the composite of ischemic stroke, admission for heart failure, and all-cause death.

RESULTS Median follow-up duration of the study cohort was 3.4 years. After adjusting for multiple variables, groups 2 and 3 were associated with a lower stroke risk (adjusted hazard ratio [aHR]: 95% confidence interval [CI]: 0.867, 0.794-0.948 and 0.713, 0.637-0.798, respectively) than that of group 1. Compared to Group 1, group 4 showed the lowest stroke risk (aHR: 0.694, 95% CI: 0.586-0.822) among all groups, followed by group 3 (0.713, 0.637-0.798) and group 2 (0.857, 0.794-0.948), respectively. Group 4 was associated with the lowest risk of all-cause death (aHR: 0.680, 95% CI: 0.613-0.754) and the composite outcome (aHR: 0.708, 95% CI: 0.649-0.772).

CONCLUSION ERC and HLS were associated with a lower risk of ischemic stroke in elderly patients with new-onset AF. Concurrently implementing ERC and maintaining HLS was associated with the lowest risk of death and the composite outcome, with a modest synergistic effect on stroke prevention.

© 2024 Lim, Lee, Choi, Lee, Han, Oh and Lip.

Keywords

atrial fibrillationelderlylifestyle modificationrhythm controlstroke

Figures

Figure 1
Figure 1 Study flow. AF, atrial fibrillation.
Figure 2
Figure 2 Cumulative incidence curves for the clinical outcomes of the study groups. (A) Ischemic stroke, (B) heart failure, (C) all-cause death, (D) composite outcome. ERC, early rhythm control; HLS, healthy lifestyle.
Figure 3
Figure 3 Adjusted hazard ratios for clinical outcomes of the study groups. *Model 3 was adjusted for age, sex, all comorbidities, CHA2DS2-VASc score, Charlson comorbidity index, all medications, body mass index, systolic blood pressure, and income. CI, confidence interval; ERC, early rhythm control; HLS, healthy lifestyle; HR, hazard ratio.

그림 출처: PubMed Central 공개 논문 (PMC10902049)

Conflict of interest statement

EK-C: Research grants or speaking fees from Abbott, Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daewoong Pharmaceutical Co., Daiichi-Sankyo, DeepQure, Dreamtech Co., Ltd., Jeil Pharmaceutical Co. Ltd, Medtronic, Samjinpharm, Seers Technology, and Skylabs. GYH-L: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 899871. No fees are received personally. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

그 밖의 정보
출판 형태
Journal Article
저널
Frontiers in cardiovascular medicine · ISSN 2297-055X
전자 출판
2024-02-15
연구비
NIEHS NIH HHS 27302C0028
참고문헌
37편